Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer

1995, Chemotherapy in non-small cell lung cancer, Br. Med. J., 311, 899, 10.1136/bmj.311.7010.899 Schiller, 2002, The Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer, N. Engl. J. Med., 346, 92, 10.1056/NEJMoa011954 Shepherd, 2000, Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy, J. Clin. Oncol., 18, 2095, 10.1200/JCO.2000.18.10.2095 Fossella, 2000, Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens, J. Clin. Oncol., 18, 2354, 10.1200/JCO.2000.18.12.2354 Huisman, 2000, Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer, J. Clin. Oncol., 18, 3722, 10.1200/JCO.2000.18.21.3722 Pohl, 1995, D-19575, Cancer Chemother. Pharmacol., 35, 364, 10.1007/s002800050248 Veyhl, 1998, Transport of the new chemotherapeutic agent beta-d-glucosylisophosphoramide mustard (D-19575) into tumor cells is mediated by the Na+-D-glucose cotransporter SAAT1, Proc. Nat. Acad. Sci. USA, 95, 2914, 10.1073/pnas.95.6.2914 Briasoulis, 2000, Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters, J. Clin. Oncol., 18, 3535, 10.1200/JCO.2000.18.20.3535 Cancer Therapy Evaluation Program. Common Toxicity Criteria, Version 2.0 (https://webapps.ctep.nci.nih.gov/ctcv2/), 1999. Fukuoka, 2003, Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer, J. Clin. Oncol., 21, 2237, 10.1200/JCO.2003.10.038 Giaccone, 2002, Lung cancer, Oncogene, 21, 6970, 10.1038/sj.onc.1205565